Based on the significant Flt3L-induced increase in cDC2s, that specialize in CD4+ T cell priming, and the striking effects of NDV on CD4+ Th1 effector cells, we sought to evaluate the role of CD4+ T cells for Flt3L+NDV-induced anti-tumor immunity in vivo. The gene discussed is FLT3LG; the disease is neoplasm.